Skip to main content
Full access
CLINICAL RESEARCH REPORTS
Published Online: 1 October 2008

Risperidone Therapy in Two Successive Pregnancies

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
M s. Z, a 23-year-old married woman from a rural background, presented with a 2-year history of undifferentiated schizophrenia (DSM-IV) with predominant symptoms of incongruent affect, bizarre delusions, and auditory hallucinations. Premorbidly, she was well-adjusted with family and friends. There was no history of substance abuse, and negative family history of psychiatric illness. Her symptoms were well controlled with risperidone, 3 mg/day. She had an unplanned pregnancy 6 months after beginning risperidone therapy. The pregnancy’s progression was normal, as were all the routine investigations including blood glucose level. Her prenatal ultrasound examination conducted at 18 weeks showed a normal pregnancy appropriate for gestational age, with no evidence of congenital malformations. Up until the end of the second trimester, she had been regular with her prenatal and psychiatric follow-up, but subsequently she refused to come in. Her father, however, remained in periodic contact with both specialists, reporting that she continued her risperidone therapy and did not show any signs of positive psychotic symptoms. She was reportedly maintaining good health, and the pregnancy was without adverse events. The patient had spontaneous labor at 39 weeks and delivered a healthy baby girl, weighing 3.2 kg. There were no postnatal complications. After the birth of the baby, Ms. Z’s dose of risperidone was reduced to 2 mg/day as she was psychiatrically stable. Nine months after the first baby, she became pregnant again while on risperidone, 2 mg/day. As before, she was regular in attending prenatal and psychiatric follow-up until the end of second trimester. However, her father was once again regular in briefing us about her condition, which did not reveal any physical or psychological complications. She was continued on the same dose of risperidone, 2 mg/day. At 39 weeks, she had an uneventful delivery of a healthy baby boy, weighing 3 kg. The babies were breastfed by their mother for 6 months. Both the children, now 36 and 18 months old, remained healthy, with no evidence of neurodevelopmental delays or any behavioral problem.
Until now we could find only one case report wherein atypical antipsychotic clozapine therapy was used successfully over two consecutive pregnancies without any postnatal complications. 1 Recent prospective studies also showed that the risk of risperidone causing poor pregnancy and fetal or natal outcome was not different from pregnancy risks for those in the general populations not exposed to this agent. 2, 3 By contrast, animal studies in rats have shown increased incidence of pup deaths and stillbirth with use of risperidone during pregnancy. 4 In humans, few cases reported that use of risperidone suggested agenesis of corpus callosum, 5 spontaneous abortions, 4 and oligohydramnios. 6 Nevertheless, our report probably suggests that risperidone may be used, though with caution, even in second a pregnancy, unless contraindicated.

Footnote

Received December 30, 2007; accepted January 3, 2008. Dr. Mendhekar is affiliated with the Neuropsychiatry and Headache Clinic in Delhi, India; Dr. Lohia is affiliated with the Department of Psychiatry at Elmhurst Hospital Center, Mount Sinai School of Medicine, in New York. Address correspondence to Dr. Dattatreya Namdeorao Mendhekar, Neuropsychiatry and Headache Clinic, 10867 Pratap Nagar, Delhi 110007, India; [email protected] (e-mail).
Copyright © 2008 American Psychiatric Publishing, Inc.

References

1.
Gupta N, Grover S: Safety of clozapine in two successive pregnancies. Can J Psychiatry 2004; 49:863
2.
McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005; 66:444–449
3.
Coppola D, Russo LJ, Kwatra RF Jr, et al: Evaluating the post-marketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. Drug Saf 2007; 30:247–264
4.
Levinson AJ, McKenna AKE, Koren G, et al: Pregnancy outcome in women receiving atypical antipsychotic drugs: a prospective, multicentre, controlled study. Schizophr Res 2003; 60(suppl 1):361
5.
Physician’s Desk Reference, 55th ed. Montvale, N.J., Medical Economics, 2001
6.
Grover S, Avasthi A: Risperidone in pregnancy: a case of oligohydramnios. German J Psychiatry 2004; 7:56–57

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 485 - 486
PubMed: 19196935

History

Published online: 1 October 2008
Published in print: Fall, 2008

Authors

Details

Dattatreya Mendhekar, M.D.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share